QIAGEN (NYSE:QGEN) and DiaSorin (OTCPK:DSRLF) announced the U.S. launch of an automated workflow for QuantiFERON-TB Plus (QFT-Plus), the fourth-generation modern gold standard for latent tuberculosis (TB) detection, on DiaSorin’s LIAISON platforms.
The FDA approved the LIAISON QuantiFERON-TB Plus Test, to offer streamlined laboratory automation for latent TB screening, supporting the conversion from tuberculin skin tests to modern blood-based QuantiFERON technology.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.